Literature DB >> 36047504

Cytotoxic and Apoptotic Effects of the Combination of Borax (Sodium Tetraborate) and 5-Fluorouracil on DLD-1 Human Colorectal Adenocarcinoma Cell Line.

Ömer Faruk Kırlangıç1, Ecem Kaya-Sezginer2, Sema Ören3, Serap Gür4, Özlem Yavuz5, Taner Özgürtaş5.   

Abstract

Objectives: Colorectal cancer (CRC) remains a crucial health problem due to the toxicity of 5-Fluorouracil (5-FU) as first-line chemotherapy agent for treating CRC. The anticancer effects of boron and its compounds have been shown in various cell lines. This study aimed to examine the cytotoxic and apoptotic effects of borax (sodium tetraborate) alone or along with 5-FU on human CRC cells, DLD-1. Materials and
Methods: Cytotoxicity and apoptosis were determined by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, 4',6-diamidino-2-phenylindole and annexin V/propidium iodide staining.
Results: The results showed that combined treatment revealed a significant time- and concentration-dependent cytotoxic effect on DLD-1 cells compared with borax or 5-FU treatment alone. The combination of borax and 5-FU induced a clear increase in the early apoptotic cell percentage, compared to the cells treated with monotherapies. Additionally, a significant increase in condensed and fragmented nuclei was detected in DLD-1 cells treated with the combination treatment compared with borax or 5-FU alone.
Conclusion: Our current findings suggest that the combination of borax with 5-FU has a strong cytotoxic and apoptotic effect on the human CRC DLD-1 cells.

Entities:  

Keywords:  5-fluorouracil; Apoptosis; DLD-1; borax; colorectal adenocarcinoma

Year:  2022        PMID: 36047504      PMCID: PMC9438760          DOI: 10.4274/tjps.galenos.2021.29726

Source DB:  PubMed          Journal:  Turk J Pharm Sci        ISSN: 1304-530X


  30 in total

Review 1.  Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

Authors:  Michael J O'Connell
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

2.  Balancing the efficacy and toxicity of chemotherapy in colorectal cancer.

Authors:  Michael S Braun; Matthew T Seymour
Journal:  Ther Adv Med Oncol       Date:  2011-01       Impact factor: 8.168

Review 3.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

4.  Cytotoxic and apoptotic effects of boron compounds on leukemia cell line.

Authors:  Zerrin Canturk; Yağmur Tunali; Seval Korkmaz; Zafer Gulbaş
Journal:  Cytotechnology       Date:  2014-08-27       Impact factor: 2.058

5.  Boric acid inhibits human prostate cancer cell proliferation.

Authors:  Wade T Barranco; Curtis D Eckhert
Journal:  Cancer Lett       Date:  2004-12-08       Impact factor: 8.679

6.  Borax-induced apoptosis in HepG2 cells involves p53, Bcl-2, and Bax.

Authors:  Y Wei; F J Yuan; W B Zhou; L Wu; L Chen; J J Wang; Y S Zhang
Journal:  Genet Mol Res       Date:  2016-06-21

Review 7.  5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future.

Authors:  Sona Vodenkova; Tomas Buchler; Klara Cervena; Veronika Veskrnova; Pavel Vodicka; Veronika Vymetalkova
Journal:  Pharmacol Ther       Date:  2019-11-19       Impact factor: 12.310

8.  Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.

Authors:  Saurabh Singh; Deepak Chitkara; Reza Mehrazin; Stephen W Behrman; Robert W Wake; Ram I Mahato
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

9.  Cinnamtannin B-1 inhibits cell survival molecules and induces apoptosis in colon cancer.

Authors:  Patrick P Carriere; Neeraj Kapur; Hina Mir; Ashley B Ward; Shailesh Singh
Journal:  Int J Oncol       Date:  2018-07-19       Impact factor: 5.650

10.  Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results.

Authors:  Özgür Albuz; Dilek Dülger; Beste Çağdaş Tunali; Feray Aydin; Selim Yalçin; Mustafa Türk
Journal:  Turk J Biol       Date:  2019-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.